Piper Jaffray analyst Christopher Raymond said Regeneron's (REGN) agreement with Express Scripts (ESRX) to improve Praluent access and
make it the exclusive PCSK9 on the latter's preferred formulary may «set a somewhat dubious precedent,» but he still sees it as a smart move that can reinvigorate Praluent growth.